7/1/2011

The FDA approved Archimedes Pharma's fentanyl nasal spray Lazanda to relieve breakthrough pain in opioid-tolerant cancer patients aged 18 and older. Archimedes expects to launch the product this year through the FDA's Risk Evaluation and Mitigation Strategy program.

Related Summaries